CPD100Li
Hypoxic Solid Tumors (e.g., Pancreatic, Prostate, Cervical, Non-Small Cell Lung, Head & Neck Cancers)
Key Facts
About Cascade Prodrug
Cascade Prodrug is a private, preclinical-stage biotech founded in 2016 and based in Seattle, WA. The company's core innovation is a hypoxia-activated prodrug platform that creates 'on-off switches' for cytotoxic agents, aiming to limit systemic toxicity and enhance drug delivery to resistant tumor regions. Its lead program, CPD100Li, is a novel N-oxide prodrug of vinblastine being developed as a standalone or combination therapy for a range of hypoxic solid tumors, including pancreatic, prostate, and non-small cell lung cancers. The company is positioned to address a significant unmet need in oncology by targeting the tumor microenvironment.
View full company profile